{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"105","upperLimit":"2397","value":"756"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"349","upperLimit":"3760","value":"1768"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"530","upperLimit":"3500","value":"1700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Day 60"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"650","upperLimit":"2340","value":"1430"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"Day 180"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"690","upperLimit":"2420","value":"1660"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Day 360"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"ALC counts trending over time.","dispersionType":"Full Range","groups":[{"description":"therapeutic autologous lymphocytes\n\ntherapeutic tumor infiltrating lymphocytes\n\nmelphalan\n\nautologous hematopoietic stem cell transplantation","id":"OG000","title":"MILs in Patients Undergoing an Autologous Peripheral SCT"}],"paramType":"MEDIAN","populationDescription":"Data was not collected on one participant at the Day 28 and 180 timepoints, and data was not collected for eight participants at the Day 360 timepoint. Data was not collected on CD3+/CD4+/CD8+ cells for all participants.","reportingStatus":"POSTED","timeFrame":"Days 14, 28, 60, 180, and 360","title":"T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)","type":"SECONDARY","unitOfMeasure":"cells per microliter"}